Melissa Bello-Perez1, Alberto Falco1, Beatriz Novoa2, Luis Perez1, Julio Coll3. 1. Instituto de Biología Molecular y Celular, Universidad Miguel Hernández (IBMC-UMH), Elche, Spain. 2. Institute of Marine Research (IIM), CSIC, Vigo, Spain. 3. Department of Biotechnology, Instituto Nacional Investigaciones y Tecnologías Agrarias y Alimentarias, INIA, Madrid, Spain.
Abstract
C-reactive proteins (CRPs) are among the faster acute-phase inflammation-responses proteins encoded by one gene (hcrp) in humans and seven genes (crp1-7) in zebrafish (Danio rerio) with importance in bacterial and viral infections. In this study, we described novel preferential bindings of 25-hydroxycholesterol (25HOCh) to CRP1-7 compared with other lipids and explored the antiviral effects of both 25HOCh and CRP1-7 against spring viremia carp virus (SVCV) infection in zebrafish. Both in silico and in vitro results confirmed the antiviral effect of 25HOCh and CRP1-7 interactions, thereby showing that the crosstalk between them differed among the zebrafish isoforms. The presence of oxidized cholesterols in human atherosclerotic plaques amplifies the importance that similar interactions may occur for vascular and/or neurodegenerative diseases during viral infections. In this context, the zebrafish model offers a genetic tool to further investigate these interactions.
C-reactive proteins (CRPs) are among the faster acute-phase inflammation-responses proteins encoded by one gene (hcrp) in humans and seven genes (crp1-7) in zebrafish (Danio rerio) with importance in bacterial and viral infections. In this study, we described novel preferential bindings of 25-hydroxycholesterol (25HOCh) to CRP1-7 compared with other lipids and explored the antiviral effects of both 25HOCh and CRP1-7 against spring viremia carp virus (SVCV) infection in zebrafish. Both in silico and in vitro results confirmed the antiviral effect of 25HOCh and CRP1-7 interactions, thereby showing that the crosstalk between them differed among the zebrafish isoforms. The presence of oxidized cholesterols in humanatherosclerotic plaques amplifies the importance that similar interactions may occur for vascular and/or neurodegenerative diseases during viral infections. In this context, the zebrafish model offers a genetic tool to further investigate these interactions.
Previous studies have shown that, in contrast to a single gene-encoding humanc-reactive protein (hCRP) [1], seven genes encode zebrafish (Danio rerio) CRP1-7 isoforms [2]. CRP molecules are present from invertebrates to vertebrates. In particular, hCRP is a crucial clinical biomarker for inflammation and most recently has been associated with relevant diseases such as those caused by cardiovascular and neurodegenerative disorders [3-5]. All circulating CRP molecules are planar oligomers of ~ 25 kDa monomers. While hCRP is pentameric (p-hCRP), zebrafishCRP5 crystallizes as trimers [6]. However, it is not yet known whether other CRP1-7 isoforms are trimeric and what are their prevalent physiological conformation(s), although some CRP1-7 isoform-dependent heterogeneous biological properties have been most recently described [6,7].Planar p-hCRP molecules show opposite lipid-recognition and functional-effector faces [5]. It is well known that the recognition face mainly binds phosphocholine heads exposed at the surface of prokaryotic/eukaryotic membranes in a Ca++ [8,9]- and phospholipase A2 [10]-dependent manner when generated in damaged tissues [5]. Triggered by CRP-Ca++-phosphocholine complexes, the functional-effector face binds C1q to activate the classical complement pathway, immunoglobulin Fc receptors to activate phagocytosis [11,12] and other ligands to activate multiple cellular functions [10]. To accomplish these various functions, hCRP shows at least 4 different conformations [5,13]: i) inactive serum-circulating p-hCRP, which is present in low concentrations in healthy humans, increasing 100- to 1000-fold after inflammation; ii) pro-inflammatory tissue-associated p-hCRP* [4]; iii) pro-inflammatory tissue-associated monomeric hCRP (m-hCRP) with wider ligand capacities which include cholesterol (Ch) [14-16] and iv) disulfide-reduced m-hCRP that activates lymphoid and many other cellular types [5,16-18]. Despite the different oligomeric structures of p-hCRP and t-CRP5 [6], their protein hydrophobic profiles, two cysteine residues per monomer, Ca++-binding amino acid sequences and location of phosphocholine (PC)-binding pockets are highly conserved [19]. On the other hand, previous transcriptomic studies on crp1-7 genes have demonstrated differential transcript expression in zebrafish tissues [2], in survivors of viral infection [20] and in mutants defective in adaptive immunity [21]. Additionally, unexpected crp1-7/CRP1-7 isoform-dependent anti-viral in vitro and in vivo activities have been described. In most of the above mentioned situations, crp2/CRP2 and crp5/CRP5 transcripts/proteins were the most modulated compared with crp1/CRP1/ and crp7/CRP7. These recent findings revealed novel anti-viral CRP1-7 direct or indirect activities in zebrafish that, to our knowledge, have not been described yet for any CRP, including hCRP. Some of the similar properties mentioned above suggest analogous biological functions for p-hCRP and CRP1-7 [7]; however, whether the CRP1-7 isoforms physiologically exist as different oligomeric structures, conformations and/or become specialized in different ligand-binding or biological functions remains largely unexplored.Widely used as a general biomarker for bacterial infection and inflammation during decades, circulating p-hCRP has been found recently within atherosclerotic lesions and was proposed as a biomarker for cardiovascular diseases [22]. Additionally, the correlation between infections and cardiovascular heart diseases in humans has been demonstrated not only for bacteria but also for several viral infections [23-26]. Thus, although circulating levels of p-hCRP were initially discovered as increasing from ~10 to >500 mg/l during acute-phase responses to bacterial infections, intermediate concentrations of 10–50 mg/l were detected also during viral infections [27], suggesting possible anti-viral function(s). Nevertheless and despite p-hCRP being one of the most investigated risk biomarker molecules in the human cardiovascular field, and an important component of the anti-bacterial innate response [9], to our knowledge, there is no evidence that p-hCRP or m-hCRP possesses antiviral function. The functional significance of the CRP oligomer-monomer conversion (and viceversa?) need to be further clarified to evaluate new chemotherapeutic targets [10,28]. Zebrafish may offer a good genetic model to explore such physiological phenomena.Using in silico and in vitro studies, we focused on the lipid-docking/binding, anti-viral activities and oligomeric forms of the zebrafishCRP1-7 isoforms and some of their transcript variants. We found that i) Ca++-independent docking/binding of CRP1-7 to Ch was higher than that to other lipids, ii) HOChs were a preferential target for CRP1-7, iii) HOChs enhanced the anti-viral direct or indirect effects by zebrafishCRP1-7 in an isoform-dependent manner, and iv) CRP2/CRP5 and numerous CRP5 transcript variants have a stronger tendency to fold as trimers than other CRP-7 molecules.
Materials and methods
In silico docking predictions between zebrafish CRP1-7 and lipids
AutoDock Vina [29] included in the PyRx program package [30] was used to predict the Gibbs free-energy of docking (ΔG) of 60 × 60 × 60 Å grids surrounding the CRP1-7 molecules. When required for comparison with the experimental data, the output ΔG energies were converted to constant inhibition (Ki) values in molar concentrations (M), using the formula Ki = exp([ΔG × 1000] / [R × T]) (R = 1.98 cal/mol, and T = 298°C)[31]. The predicted structures were visualized in PyRx and/or PyMOL (https://www.pymol.org/).
Cell culture in EPC cell monolayers
Epithelioma papulosum cyprinid (EPC) cells from fathead minnow fish (Pimephales promelas) were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA; code number CRL-2872). EPC cell monolayers were grown at 26°C in a 5% CO2 atmosphere in RPMI-1640 Dutch modified cell culture medium supplemented with 20 mM HEPES, 10% fetal bovine serum, FBS (Sigma, St. Louis, USA), 1 mM pyruvate, 2 mM glutamine, 50 μg/ml of gentamicin (Gibco) and 2 μg/ml of fungizone [21].
Preparation of spring viremia of carp virus (SVCV)
The isolate 56/70 of spring viremia carp virus (SVCV) from carpC. carpio [32], recently renamed Carp sprivivirus [33], was replicated in EPC cell monolayers at 26°C, in the cell culture media described above except for 2% FBS and the absence of the CO2 atmosphere. Supernatants from SVCV-infected EPC cell monolayers were clarified by centrifugation at 4000 g for 30 min and kept at -80°C [21].
Estimation of the effects of methyl-betacyclodextrin (MBCD) on SVCV infectivity
EPC cell monolayers treated for 2 h with different concentrations (0–8 mM) of MBCD were incubated with SVCV for 24 h and then were assayed for fluorescent focus-forming units (ffu) (see later). The results were expressed as the percentage of SVCV infectivity calculated by the following formula: 100 × (ffu treated with MBCD / ffu nontreated with MBCD). To assay for viability, EPC cell monolayers treated with MBCD as above were incubated with 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in a Krebs–Hensleit–HEPES buffer (115 mM NaCl, 5 mM KCl, 1 mM KH2PO4, 1.2 mM MgSO4, 2 mM CaCl2, and 25 mM HEPES at pH 7.4) for 3 h, the absorbance at 570 nm was measured, and the percentage of viability was calculated by the following formula: absorbance of MBCD treated cells / absorbance of untreated cells. Means and standard deviations (n = 2) were interpolated and smoothed using the cubic B-spline method in Origin Pro 2017 (Northampton, MA, USA).
Construction of recombinant pRSET-CRP1-7 for E.coli expression
The corresponding mRNA sequences of the CRP1-7 proteins [7] were used for the design, construction and expression in E.coli. All the corresponding synthetic DNA sequences were cloned into the pRSET adding poly-histidine tails (polyH) at their C-terminal ends (GeneArt, Regensburg, Germany). The purified plasmids were then transfected into E.coliBL21(DE3) and grown at 37°C. The resulting recombinant bacteria from the pRSET-crp1-7 constructs were induced with IPTG at 25°C. Gradient 4–20% polyacrylamide gel electrophoresis (PAGE) and Western blotting were used to detect CRP1-7 expression.
Construction of recombinant rCRP1, rCRP2, rCRP5, rCRP7 for insect expression
The mRNA sequences of CRP1, CRP2, CRP5 and CRP7 described previously [7], were used for the design, construction and expression in insect cells (GenScript, Piscataway, NJ, USA). Briefly, target DNA containing the gp67 signal peptide + CRP1-7 + Flag (DYKDDDK) + 6 x polyHis sequences (construct size of ~ 3 Kbp) were synthesized and subcloned into the pFastBac1TM baculovirus transfer vector (Invitrogen). The pFastBac1 recombinants were transfected into DH10 BacTM-competent E. coli cells and bacmids prepared from selected E. coli clones. Next, recombinant baculoviruses were generated in Spodoptera frugiperda (Sf9) insect cells. For that, Sf9 cells cultured in Grace’s insect media (Gibco BRL) with 10% foetal bovine serum, 3% nonessential amino acids and 20 μg/ml gentamicin at 28°C [34] were cotransfected with bacmids and baculovirus using Cellfectin II. The supernatants containing the recombinant baculoviruses were obtained 72 h posttransfection with titers of ~ 107 pfu/ml.For rCRP expression and purification, 500 ml of Sf9 cell supernatants were harvested 72 h postinfection and were dialyzed against 50 mM Tris, pH 8.0, 500 mM NaCl. The rCRP-containing medium was incubated with Flag or Ni++ columns equilibrated with 50 mM Tris, 500 mM NaCl, 5% glycerol, pH 8.0, eluted with 200 μg/ml of the Flag peptide or 150 mM imidazole, dialyzed against equilibration buffer and kept at -20°C until ready for use. Purified rCRPs were loaded onto 8–20% SDS-polyacrylamide gels (BioRad), electrophoresed, and transferred to nitrocellulose membranes (Schleicher & Schuell) to detect specific tag epitopes. The membranes were blocked with phosphate buffered saline containing 0.05% Tween 20 and 4% skim milk, and then were incubated with anti-poly-H monoclonal antibody MAb (Sigma) for 1 h, followed by incubation with anti-mousehorseradish peroxidase-conjugated immunoglobulins (Sigma) and visualization with diaminobenzidine (DAB). The protein concentrations were determined using the bicinchoninic acid (BCA) method [35] and were confirmed by PAGE with BSA as the standard.
Production of rabbit antibodies to recognize zebrafish CRP1-7 isoforms
To detect CRP1-7 isoforms in lipid-binding assays and after PAGE by Western blotting, anti-CRP1-7rabbit antibodies (GenScript, Piscataway, NJ, USA) were raised against 3 of the longest more conserved amino acid stretches such as peptide p1 (18SYVKLSPEKPLSLSAFTLC), peptide p2 (189DWDTIEYDVTGN) and peptide p3 (129RPGGTVLLGQDPDSYVGSFC). All p1, p2 and p3 were located at the CRP1-7 surface, as shown by PyMOL modelling of trimeric CRP5 ± Ca++ (4PBP.pdb and 4PBO.pdb, respectively) [6] (data not shown). To reduce assay backgrounds, the anti-peptide antibodies were purified by affinity chromatography against the corresponding syntheticpeptides coupled to CNBr-activated Sepharose. Only the affinity-purified anti-p3 antibodies bound purified insect-made rCRP2, rCRP5 and rCRP7 on Western blots under denaturing and nondenaturing conditions and recognized EPC cells transfected with pMCV1.4-crp2-7 by immunofluorescence (data not shown).
Binding of CRP1-7 to solid-phase lipids
The binding of CRP1-7 to lipids was assayed in solid-phase 96-well plates (Nunc, Maxisorb) by modifying previously described methods [36]. The wells were coated to dryness with several concentrations of ethanol-dissolved lipids and were kept dried until ready for use. To assay for CRP1-7 binding, the plates were first washed with 0.1 M sodium borate, 1 mM CaCl2 buffer, pH 8, and then 0.5 μg/well of rCRPs or 10-fold diluted ssCRP1-7 added in 50 μl of the same buffer and incubated for 60 min. After washing, bound CRP1-7 were detected with rabbit anti-p3 and peroxidase-labelled goat anti-rabbit IgG. Peroxidase was finally assayed with OPD as described previously [37,38]. The resulting data were interpolated and smoothed by the cubic B-spline method using Origin Pro 2017 (Northampton, MA, USA).
Binding of CRP5 pepscan peptides to solid-phase 25HOCh and docking predictions
A series of 15-mer peptides overlapping 5 amino acids of the CRP5 sequence was chemically synthesized by adding an amino-terminal biotin molecule (Chiron Mimotopes, Victoria, Australia). The syntheticpepscan peptides were diluted in distilled water to 4 mg/ml and were kept frozen until use.To perform the binding experiments, 2 μg of 25HOCh was dissolved in 50 μl of ethanol and was dried into polystyrene wells of 96-well Nunc Maxisorb plates. After washing the plates with 0.1 M borate buffer pH 8, 1 mM CaCl2, pepscan peptides (0.05 μg in 50 μl) were added to each of the wells and were incubated for 60 min. After washing, 1000-fold diluted peroxidase-labelled streptavidin were added and incubated for 30 min. After the last wash, OPD was used to detect the amount of peroxidase as described previously [38].To perform the in silico docking predictions, the best modelled CRP5 pepscan peptide sequences predicted in solution by the Mobyle program http://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py#forms::PEP-FOLD [39] were docked to all possible predicted conformations of 25HOCh. All the resulting docking data were interpolated and smoothed using the cubic B-spline method in Origin Pro 2017 (Northampton, MA, USA) and the data that best fitted pepscan binding were selected for representation. Validation of such strategy was confirmed by the high correlation obtained among similarly modeled VHSV G protein pepscan 15-mer peptides and previously published binding data to labeled phosphatidylserine [40] and phosphatidylinositol-bisphosphate [41] (data not shown).
Preparation of pMCV1.4 plasmids encoding crp1-7
Each of the chemically synthesized crp1-7 and green fluorescent protein (gfp) genes was subcloned into the pMCV1.4 plasmid as described previously [7]. The resulting pMCV1.4-crp1-7 and pMCV1.4-gfp plasmid constructs were used to transform E.coli DH5alpha, amplified and isolated using the Endofree Plasmid Midi purification Kit (Qiagen, Germany). Purified plasmid solutions containing 80–100% of plasmid DNA, as shown by agarose gel electrophoresis were stored at -20°C.
Preparation of CRP1-7-enriched supernatants
To produce ml amounts of CRP1-7-enriched supernatants (ssCRP1-7), 60% confluent EPC cell monolayers in 25 cm2 bottles in 5 ml of cell culture medium were transfected with 5 μg of each of the pMCV1.4-crp1-7 plasmids complexed with 15 μl of FuGENE HD (Promega, Madison, WI, USA) for 24 h at 22° C (transfection efficiency of 15.2–30.4%, n = 3 as estimated by transfection with pMCV1.4-gfp). After washing with fresh cell culture medium, the ssCRP1-7 were harvested 3-days later, the cell debris was eliminated by centrifugation, and the supernatants were sterilized by filtration through 0.2 μ filters and stored in aliquots at -80°C until ready for use [7].
SVCV infection of preincubated EPC cell monolayers with 25HOCh and ssCRP1-7
To detect the effects of 25HOCh and ssCRP1-7 (25HOCh + ssCRP1-7) on SVCV infection, the concentrations of 25HOCh, and ssCRP1-7, as well as the multiplicity of infection (m.o.i.) of SVCV were first optimized (data not shown). Optimal conditions were obtained when the EPC cell monolayers were pre-incubated with 100 μl of 4-fold diluted ssCRP1-7 or ssGFP in RPMI with 2% FBS in the absence or presence of 10 μM 25HOCh for 20 h at 26°C, the monolayers were washed twice, and SVCV was added at 10−2 m.o.i. To estimate the extent of SVCV infection, the monolayers were incubated with SVCV for 2 h, washed, and incubated for 24 h at 26°C. The number of infected EPC cells was estimated by flow cytometry after staining with monoclonal anti-SVCV (BioX Diagnostics SA, Jemelle, Belgium) and fluorescein-labelled goat anti-mouse immunoglobulins as described previously [7]. The number of EPC infected cells varied from 29.6–39.7% or 9.9–20.1% (n = 3) after preincubation of the EPC cell monolayers with either 25HOCh or ssCRP1-7 alone, respectively. The results of preincubation with 25HOCh + ssCRP1-7 were expressed as relative percentages of infection ± 25HOCh calculated by the following formula, 100 × (percentage of infected EPC cells preincubated with 25HOCh + CRP1-7 / percentage of infected EPC cells preincubated in absence of 25HOCh and presence of CRP1-7).
In silico modeling of CRP1-7 tridimensional structures
To explore the CRP1-7 tridimensional structures, their protein sequences were automatically modelled (RMSD<0.3 Ă) using the SWISS-MODEL homology server (https://swissmodel.expasy.org/interactive) [42-44]. The tridimensional structures of the target CRP1-7 sequences were predicted after pairwise comparison of the interfaces between the target and best template selected by the program. For each possible interface with > 10 residue-residue interactions, the QscoreOligomer score was calculated and averaged from all predicted interfaces [42,45]. The templates that resulted selected by automatic modeling corresponded to zebrafishCRP5 ± Ca++ (4PBP.pdb and 4PBO.pdb) [6] (RCSB data bank at http://www.rcsb.org/pdb/home/home.do).
Results
Preferential docking predictions of zebrafish CRP1-7 to Ch
To predict their docking ΔG energies to CRP1-7, the phosphocholine head (PC), other phospholipid heads [46-48] and cholesterol (Ch) [16] were selected because of their hCRP ligand properties. Interestingly, the results predicted the lowest ΔG (stronger binding) for Ch (ΔG ranges from -7.5 to -9 Kcal/mol) compared with phospholipid-heads (ΔG ranges from -4 to -5.5 Kcal/mol). The addition of a glycerol molecule to the phospholipid-heads did not change their predicted ΔG (S1 Table). The results also predicted that Ch docking energies were more Ca++-independent than most other lipid-heads (Fig 1A) and predicted alternative docking locations for Ch and other lipid-heads (data not shown). These results were in contrast to the traditionally described phosphatidylcholine-binding preferences of hCRP [46-49]. Thus, although the Ch-binding properties of hCRP were described previously, their stronger binding energies were not [16]. Similar Ch-binding preferences were obtained by docking predictions made in parallel for hCRP and CRP1-7 (S1 Table).
Fig 1
CRP1-7 preferential docking to Ch (A) and inhibition of SVCV infectivity by methyl-betacyclodextrin (MBCD) (B). A) Docking predictions to selected lipid-heads and Ch. CRP1-7 were SWISS-modeled using as templates CRP5 (GenBank accession number JF772178.1), 4PBP.pdb (+Ca) and 4PBO.pdb (-Ca) 3D-structures [6]. The structures were extracted from *.sdf from PubChem (https://pubchem.ncbi.nlm.nih.gov/search/search.cgi) and converted to *.pdbqt using the Babel program from the PyRx package [30]. PC, phosphocholine. PE, phosphoethanolamine. PS, phosphoserine. SPG, palmitoyl sphingomyelin. Ch, cholesterol. Numbers before the names_, PubMed ID numbers. Blue open circles, consecutive CRP1-7 isoforms from left to right in the absence of Ca++. Black open circles, consecutive CRP1-7 isoforms from left to right in the presence of Ca++. Red circles, CRP5. Black lines, +Ca++. Dot lines, -Ca++. B) Effect of methyl-betacyclodextrin (MBCD) on SVCV infectivity. MBCD-treated EPC cell monolayers were incubated with SVCV for 24 h and were assayed for ffu. The results were expressed as infectivity percentages calculated by the following formula, 100 × (ffu treated with MBCD / ffu nontreated with MBCD). To assay for viability, MBCD-treated EPC cell monolayers were incubated with MTT for 3 h, the absorbance at 570 nm was measured and the percentage of viability calculated using the following formula: absorbance of treated cells / absorbance of untreated cells. Open blue or black circles and their vertical lines, means and standard deviations (n = 2), respectively. The data were then interpolated and smoothed using the cubic B-spline method in Origin Pro 2017 (Northampton, MA, USA). Black line, SVCV infectivity. Blue dashed line, EPC cell monolayer viability.
CRP1-7 preferential docking to Ch (A) and inhibition of SVCV infectivity by methyl-betacyclodextrin (MBCD) (B). A) Docking predictions to selected lipid-heads and Ch. CRP1-7 were SWISS-modeled using as templates CRP5 (GenBank accession number JF772178.1), 4PBP.pdb (+Ca) and 4PBO.pdb (-Ca) 3D-structures [6]. The structures were extracted from *.sdf from PubChem (https://pubchem.ncbi.nlm.nih.gov/search/search.cgi) and converted to *.pdbqt using the Babel program from the PyRx package [30]. PC, phosphocholine. PE, phosphoethanolamine. PS, phosphoserine. SPG, palmitoyl sphingomyelin. Ch, cholesterol. Numbers before the names_, PubMed ID numbers. Blue open circles, consecutive CRP1-7 isoforms from left to right in the absence of Ca++. Black open circles, consecutive CRP1-7 isoforms from left to right in the presence of Ca++. Red circles, CRP5. Black lines, +Ca++. Dot lines, -Ca++. B) Effect of methyl-betacyclodextrin (MBCD) on SVCV infectivity. MBCD-treated EPC cell monolayers were incubated with SVCV for 24 h and were assayed for ffu. The results were expressed as infectivity percentages calculated by the following formula, 100 × (ffu treated with MBCD / ffu nontreated with MBCD). To assay for viability, MBCD-treated EPC cell monolayers were incubated with MTT for 3 h, the absorbance at 570 nm was measured and the percentage of viability calculated using the following formula: absorbance of treated cells / absorbance of untreated cells. Open blue or black circles and their vertical lines, means and standard deviations (n = 2), respectively. The data were then interpolated and smoothed using the cubic B-spline method in Origin Pro 2017 (Northampton, MA, USA). Black line, SVCV infectivity. Blue dashed line, EPC cell monolayer viability.
Membrane Ch sequestration by methyl-betacyclodextrin reduces SVCV infection
To explore whether Ch could be implicated in SVCV infections, EPC cell monolayers were pretreated with methyl-betacyclodextrin (MBCD), a sequestering agent for membrane Ch [50]. Treatment with MBCD from 0.5 to 8 mM lowered the SVCV infectivity to ~ 20% (Fig 1B, black line), while those concentrations exerted no significative effects on cell survival (Fig 1B, blue dashed line). These results confirmed that the presence of Ch in the cell membranes was required for SVCV infectivity. Similar anti-viral activities of MBCD have been described, for instance, for poliovirus [51], pseudorabies [52], hepatitis [53], Sendai [54] and influenza [50,55] viruses. Therefore, these results suggest that the Ch-CRP1-7 interaction may interfere with SVCV infectivity.Because Ch-containing lipid rafts participate in interactions with hCRP [56], Ch is a key molecule involved in coronary diseases and Ch-related physiological compounds are highly diverse, an screening for other physiological Ch-related compounds was performed before studying any possible interactions among CRP1-7, Ch and viral infections.
Preferential predicted docking of zebrafish rCRPs to hydroxycholesterols (HOChs)
When 26 Ch-related physiological compounds were docked in silico to the modeled tridimensional structures of CRP1-7, stronger binding predictions (ΔG ranges between -7.5 to -9.3 Kcal/mol) were obtained for most of the hydroxy derivatives studied for CRP1-7 (Fig 2 and S2 Table). The ΔG values obtained in the absence or in the presence of Ca++ were not significantly different (S2 Table). Most of the lowest ΔG values were obtained for CRP1, while CRP5 showed ~ 0.5–1 Kcal/mol higher ΔG than CRP1, depending on the Ch-related molecule. The most relevant results of these Ch-related docking predictions could be summarized as follows: i) water-soluble hydroxy Ch derivatives (HOChs) interacted with CRP1-7 within the lower ΔG ranges from -8.0 to -9 Kcal/mol; ii) among the HOChs, most of the lower ΔG values corresponded to CRP1, while most of the highest ΔG values corresponded to CRP5; and iii) 25-hydroxycholesterol (25HOCh) was unique among all the studied HOChs because of their lowest ΔG values (~ -9 Kcal/mol). No previous reports on 25HOCh-CRP interactions could be found in the literature.
Fig 2
CRP1-7 docking predictions to several Ch-related physiological compounds.
CRP1-7 models, Ch-related physiological molecules and ΔG predictions were obtained as described in the legend of Fig 1A. Because the predicted ΔG values in the absence or presence of Ca++ were similar (S2 Table), only the mean ΔGs ± Ca++ were represented. Open circles, consecutive CRP1-7 isoforms from left to right. Red circles, CRP5. Numbers before the names_, PubMed ID numbers. HO, hydroxy. Ch, cholesterol.
CRP1-7 docking predictions to several Ch-related physiological compounds.
CRP1-7 models, Ch-related physiological molecules and ΔG predictions were obtained as described in the legend of Fig 1A. Because the predicted ΔG values in the absence or presence of Ca++ were similar (S2 Table), only the mean ΔGs ± Ca++ were represented. Open circles, consecutive CRP1-7 isoforms from left to right. Red circles, CRP5. Numbers before the names_, PubMed ID numbers. HO, hydroxy. Ch, cholesterol.To explore the existence of other possible Ch-related compounds with still lower ΔG values that could be used as anti-inflammatory chemotherapeutic drugs, a library of 1093 Ch-related synthetic molecules was docked to modeled CRP1-7 tridimensional structures. The frequency distribution of the predicted ΔGs showed a distribution with a mean ± 3 standard deviations = -12 Kcal/mol (S3 Table). Twenty-one Ch-related nonphysiological or synthetic compounds showed the lowest ΔG values from -13.3 to -12 Kcal/mol (Table 1). Most of the new molecules identified contained deuterium, fluorine, bromine or chlorine atoms and 66.6% contained at least one hydroxy group per molecule. Therefore, some of these newly identified Ch-related derivatives could be further employed for drug applications and/or mechanistic studies in the future. Next we tried to confirm some of the docking predictions mentioned above by solid-phase binding assays.
Table 1
Ch-related nonphysiological compounds with the best docking predictions to CRP1-7.
ID
Name
CRP
ΔG, Kcal/mol
71749935
M Progesterone-d3 Glucuronide
CRP5
-13.3
70626502
25-F-1α-HOCh
CRP1
-13.3
71749934
M Progesterone Glucuronide
CRP5
-13.3
70626891
diF-methyl-dodecahydro-cyclopentaphenanthrene
CRP1
-13.0
493972
F-11-HO-Methyl-DioxoPregnadien-Acetate
CRP5
-12.6
192154
triFlumedroxone Acetate
CRP5
-12.6
240767
Fmetholone 17 Acetate
CRP5
-12.5
95574
F-16a,17-(isopropylidenedioxy) Corticosterone
CRP5
-12.5
71748935
20-HOCh-d7
CRP5
-12.4
21122966
6-HO-M Progesterone 17-Acetate
CRP5
-12.3
102276261
3-[(2-B-ethyl)Carbamoyl]Ch
CRP5
-12.3
71749110
HO-M Progesterone 17-Acetate
CRP5
-12.2
71748841
4–7 HOcholestenone-d7
CRP1
-12.1
57357615
17-(Acetyloxy)-C-(C-methyl)Pregnadienedione
CRP5
-12.1
126456352
24-HOCh-d4
CRP1
-12.1
71748930
4-HOCh-d7 4-Acetate
CRP5
-12.1
71315435
Cortexone M-d9
CRP1
-12.1
10476437
Flugestone 17-Acetate
CRP5
-12
71315435
Cortexone M-d9
CRP5
-12
71315434
Cortexone M-d8
CRP1
-12
71315434
Cortexone M-d8
CRP5
-12
Ch-related nonphysiological compound structures were retrieved from several libraries obtained from PubChem in a *.sdf format. To construct the library, 550 Chs, 314 colestens, 73 corticosterones, 41 dehydroepiandrosterones (DHEAs), 107 estriols, 99 pregnenolones, 196 progesterones and 107 HOChs were retrieved. Duplicated and extremely long molecules were eliminated from the total of 1487 *.sdf, resulting in a downsized library of 1093 *.pdbqt archives. After docking, the frequency distribution of ΔG showed two peaks with means at -11 and -7 Kcal/mol, respectively (S3 Table). Only Ch-related compounds with ΔG < -12 Kcal/mol (mean + 3 standard deviations) are shown. ID, PubMed number. HO, hydroxy. d, deuterium. F, fluoro-. C, chloro-. B, bromo. M, 17-acetyl-6,10,13-trimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodeca HOcyclopenta[a]phenanthren-16-yl) acetate (medroxy).
Ch-related nonphysiological compound structures were retrieved from several libraries obtained from PubChem in a *.sdf format. To construct the library, 550 Chs, 314 colestens, 73 corticosterones, 41 dehydroepiandrosterones (DHEAs), 107 estriols, 99 pregnenolones, 196 progesterones and 107 HOChs were retrieved. Duplicated and extremely long molecules were eliminated from the total of 1487 *.sdf, resulting in a downsized library of 1093 *.pdbqt archives. After docking, the frequency distribution of ΔG showed two peaks with means at -11 and -7 Kcal/mol, respectively (S3 Table). Only Ch-related compounds with ΔG < -12 Kcal/mol (mean + 3 standard deviations) are shown. ID, PubMed number. HO, hydroxy. d, deuterium. F, fluoro-. C, chloro-. B, bromo. M, 17-acetyl-6,10,13-trimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodeca HOcyclopenta[a]phenanthren-16-yl) acetate (medroxy).
Binding of zebrafish rCRPs to hydroxycholesterols (HOChs), Ch and PC
Because of the recently described anti-viral activities of 25HOCh [57,58] and its highest predicted docking to CRP1-7, its binding was compared with Ch/PC (the former because it is the traditional ligand for hCRP). For the binding assays, we used polystyrene wells coated with the lipids [36]. Using 25HOCh to coat the solid-phase, the binding results confirmed the higher docking of rCRP5/rCRP7 to Ch/25HOCh than to PC (Fig 3A). The binding of rCRP7 to Ch/25HOCh was slightly higher than to rCRP2 or rCRP5 (Fig 3, rCRP7) whereas rCRP2/rCRP5 binding to Ch or PC were relatively low (Fig 3, rCRP2 and rCRP5). To complete the study, we explored all isoforms for binding to 25HOCh using supernatants from EPC cells transfected with pMCV.4-crp1-7 (ssCRP1-7) as a source for CRP1-7. The results of these experiments showed different concentration-dependent profiles for different CRP1-7, with CRP1 being the most active at the lower 25HOCh concentrations assayed (<10 μM) (Fig 3B and S4 Table) confirming the docking predictions. On the other hand, although CRP7 showed slightly higher binding at >100 μM 25HOCh, similar values were obtained for all ssCRP1-7 at those higher concentrations. The binding of ssCRP1-7 to solid-phase 25HOCh showed relatively lower values than that to rCRPs, most probably due to the lower CRP concentrations in the ssCRP1-7 (compare the ordinate values of Fig 3A and 3B).
Fig 3
rCRP (A) and ssCRP1-7 (B) binding to solid-phase lipids. The binding of purified rCRPs and ssCRP1-7 to selected lipids was assayed by using 96-well plates coated to dryness with several lipid concentrations dissolved in ethanol. The lipid-coated plates were washed and were incubated with rCRP2 or ssCRP1-7 in borate buffer for 1 h in a 50 μl volume. To detect bound rCRP or ssCRP1-7, rabbit anti-CRP p3 peptide, peroxidase-labeled goat anti-rabbit IgG and OPD were used as described previously [37,38]. The means and standard deviation from 2 independent experiments were represented. A) rCRP at 0.5 μg/well in borate buffer. Open triangles, solid-phase phosphatidylcholine (PC). Open circles, solid-phase Ch. Black circles, solid-phase 25HOCh. B) ssCRP1-7 were 10-fold diluted in borate buffer. Results from one experiment out of three were interpolated and smoothed using the cubic B-spline method in Origin Pro 2017 (Northampton, MA, USA) (see data in S4 Table). Black points, supernatant from pMCV1.4-gfp transfected cells. Blue line, supernatant from pMCV1.4-crp1 transfected cells. Green line, supernatant from pMCV1.4-crp2 transfected cells. Light-blue line, supernatant from pMCV1.4-crp3 transfected cells. Gray line, supernatant from pMCV1.4-crp4 transfected cells. Red line, supernatant from pMCV1.4-crp5 transfected cells. Orange line, supernatant from pMCV1.4-crp6 transfected cells. Purple line, supernatant from pMCV1.4-crp7 transfected cells.
rCRP (A) and ssCRP1-7 (B) binding to solid-phase lipids. The binding of purified rCRPs and ssCRP1-7 to selected lipids was assayed by using 96-well plates coated to dryness with several lipid concentrations dissolved in ethanol. The lipid-coated plates were washed and were incubated with rCRP2 or ssCRP1-7 in borate buffer for 1 h in a 50 μl volume. To detect bound rCRP or ssCRP1-7, rabbit anti-CRP p3 peptide, peroxidase-labeled goat anti-rabbit IgG and OPD were used as described previously [37,38]. The means and standard deviation from 2 independent experiments were represented. A) rCRP at 0.5 μg/well in borate buffer. Open triangles, solid-phase phosphatidylcholine (PC). Open circles, solid-phase Ch. Black circles, solid-phase 25HOCh. B) ssCRP1-7 were 10-fold diluted in borate buffer. Results from one experiment out of three were interpolated and smoothed using the cubic B-spline method in Origin Pro 2017 (Northampton, MA, USA) (see data in S4 Table). Black points, supernatant from pMCV1.4-gfp transfected cells. Blue line, supernatant from pMCV1.4-crp1 transfected cells. Green line, supernatant from pMCV1.4-crp2 transfected cells. Light-blue line, supernatant from pMCV1.4-crp3 transfected cells. Gray line, supernatant from pMCV1.4-crp4 transfected cells. Red line, supernatant from pMCV1.4-crp5 transfected cells. Orange line, supernatant from pMCV1.4-crp6 transfected cells. Purple line, supernatant from pMCV1.4-crp7 transfected cells.
Mapping of both binding and docking energies of CRP5 to 25HOCh
To further clarify 25HOCh binding to CRP1-7, we performed a pepscan approximation to map the interaction. Because m-hCRP, but not p-hCRP is the conformation that preferentially binds Ch [16,17,59], some nonconformational motifs may conserve Ch-/25HOCh-binding activity and thus a pepscan may be used to map at least some conformation-independent binding. Therefore, we selected a pepscan to explore for possible non-conformational interactions of CRP5 with 25HOCh using both solid-phase binding assays and docking predictions.For the peptide binding assays, each of the synthetically biotinylated 15-mer peptides derived from the CRP5 amino acid sequence was incubated with 25HOCh-coated solid-phases. The results showed maximal binding peaks at the ~ 30–50, 70–90, 110–150 and 170–190 amino acid positions (Fig 4A, black line). Similar peaks docked with minimal ΔG to 25HOCh (Fig 4A, blue line). Of the 25HOCh binding/docking peaks identified, only the 30–50 was in a similar region to that of the 35–47 peptide previously identified in hCRP as the main Ch-binding domain [16]. To locate the predicted interaction of 25HOCh with the CRP1-7 tridimensional structures we used PyMol. The 25HOCh docked at the CRP5 interface side with ΔG between -7.5 and -8.4 Kcal/mol (some of the contact positions at T41, E48, R71, F84, F85, S117) (Fig 4A, CRP5). By contrast, the 25HOCh docked at other CRP1-7 effector faces under the α-helix with ΔG between -8.6 and -9.1 Kcal/mol (some of the contact positions for CRP1 at R113, S115, G153, E154, Y161, and E206) (Fig 4B, CRP1). Similar ΔG values (S5 Table) and docking locations were predicted for m- or t-CRP5. Similar docking locations were predicted for 25HOCh and Ch for most CRP1-7 within ± ΔG > ~0.5 Kcal /mol (S5 Table).
Fig 4
Solid-phase binding and docking predictions to 25HOCh of CRP5 pepscan peptides (A) and predicted best docking location (B). A) For the peptide-binding assays, a series of 15-mer peptides overlapping 5 amino acids from CRP5 was chemically synthesized by adding an amino-terminal biotin molecule. Solid-phases were coated with 2 μg per well of 25HOCh into polystyrene 96-well plates. The binding of 0.05 μg of biotinylated pepscan peptides, detection with peroxidase-labeled streptavidin and staining with OPD were then performed. The means from 3 independent experiments were represented and standard deviations omitted for clarity (S5 Table). For the in silico docking predictions, the modeled pepscan peptides with the lowest energies were docked to several possible conformations of 25HOCh as described in the methods section. The docking energies that best fitted the binding data were then represented (S5 Table). Black line, peptide binding to 25HOCh. Blue line, predicted ΔG energy of peptide docking to 25HOCh. B) PyMOL representation of the lowest energy structures of CRP5 and CRP1 complexed to 25HOCh (the remaining CRP1-7 were similar). Green, CRP amino acid chains. Red, 25HOCh. Blue circles, Ca++ atoms located at the PC-binding pocket [6].
Solid-phase binding and docking predictions to 25HOCh of CRP5 pepscan peptides (A) and predicted best docking location (B). A) For the peptide-binding assays, a series of 15-mer peptides overlapping 5 amino acids from CRP5 was chemically synthesized by adding an amino-terminal biotin molecule. Solid-phases were coated with 2 μg per well of 25HOCh into polystyrene 96-well plates. The binding of 0.05 μg of biotinylated pepscan peptides, detection with peroxidase-labeled streptavidin and staining with OPD were then performed. The means from 3 independent experiments were represented and standard deviations omitted for clarity (S5 Table). For the in silico docking predictions, the modeled pepscan peptides with the lowest energies were docked to several possible conformations of 25HOCh as described in the methods section. The docking energies that best fitted the binding data were then represented (S5 Table). Black line, peptide binding to 25HOCh. Blue line, predicted ΔG energy of peptide docking to 25HOCh. B) PyMOL representation of the lowest energy structures of CRP5 and CRP1 complexed to 25HOCh (the remaining CRP1-7 were similar). Green, CRP amino acid chains. Red, 25HOCh. Blue circles, Ca++ atoms located at the PC-binding pocket [6].Therefore, both the pepscan binding and docking predictions, confirmed the existence of an interaction between 25HOCh and CRP5, which most likely can be extended to all CRP1-7.
In vitro anti-SVCV effects caused by CRP1-7 in the presence of 25HOCh
Hydroxylated Chs (HOChs) are Ch oxidized derivatives with diverse biological activities, most of them correlating with inflammatory responses [60] similar to CRP. Among the HOChs, 25HOCh showed minimal ΔG docking predictions for CRP1-7 (-8 to -9 Kcal/mol, corresponding to concentrations between 1.35 and 0.35 μM) (Fig 3). Among their biological activities, 25HOCh has been related to viral infections [58,61], including the reduction of spring viremia carp virus (SVCV) infection in zebrafish [57]. Because of the Ch-dependence of SVCV infection (Fig 1B), the reduction of SVCV infection by zebrafish ssCRP1-7 [7] was chosen as an example of possible CRP1-7- HOChs interactions affecting the same biological function.Because both 25HOCh [57] and CRP1-7 [7] have demonstrated their independent anti-SVCV activities, their concentrations were first independently titrated at different multiplicities of infection (m.o.i.) of SVCV to maximize the limits of detection when they were to be used together. Under those optimal conditions, the extent of SVCV infections obtained using ssCRP1-7 + 25HOCh (ssCRP1-7 + 25HOCh/ssCRP1-7 ratios) compared with 25HOCh (GFP + 25HOCh) were further reduced by 1.5 to 3-fold depending on the CRP1-7 isoform (Fig 5A). Similar results were obtained with rCRP5 and rCRP7 but not with rCRP2 (data not shown). The above results suggested that 25HOCh in the presence of CRP1-7 further enhanced the anti-viral effects caused by either 25HOCh or CRP1-7 alone. It is still too early to know the mechanisms implicated, because the interaction of 25HOCh with the L polymerase of SVCV [57], or inhibition of glycosylation by 25HOCh in other rhabdoviruses [62], may suggest that the binding of 25HOCh to some viral proteins cannot be excluded. Furthermore, other possible interactions among 25HOCh, CRP (direct effect) and/or other CRP-induced molecules (indirect effects) present in ssCRP1-7, may still explain the above mentioned antiviral effects.
Fig 5
Anti-SVCV infectivity after treatment of EPC cell monolayers with 25HOCh and CRP1-7.
A) EPC cell monolayers were incubated with 100 μl of ssGFP or ssCRP1-7 4-fold diluted in RPMI with 2% FBS ± 10 μM 25HOCh for 20 h at 26°C. After washing, 10−2 m.o.i of SVCV were added and incubated for 24 h. After staining with anti-SVCV and fluorescein-labeled goat anti-mouse immunoglobulins [7], the number of fluorescent cells were estimated by flow cytometry. B) Representative aspects of histograms from nonfluorescent and fluorescent cells. The number of SVCV-infected EPC cells varied from 12.7 to 50.6% (n = 5), depending on the experiment. The results were expressed as relative infection percentages calculated by the following formula, 100 × (number of infected cells+25HOCh / number of infected cells -25HOCh). The means and standard deviations of a representative experiment were represented (n = 3). *, statistically < than cells transfected with ssGFP at p < 0.05 (Student's t-test).
Anti-SVCV infectivity after treatment of EPC cell monolayers with 25HOCh and CRP1-7.
A) EPC cell monolayers were incubated with 100 μl of ssGFP or ssCRP1-7 4-fold diluted in RPMI with 2% FBS ± 10 μM 25HOCh for 20 h at 26°C. After washing, 10−2 m.o.i of SVCV were added and incubated for 24 h. After staining with anti-SVCV and fluorescein-labeled goat anti-mouse immunoglobulins [7], the number of fluorescent cells were estimated by flow cytometry. B) Representative aspects of histograms from nonfluorescent and fluorescent cells. The number of SVCV-infected EPC cells varied from 12.7 to 50.6% (n = 5), depending on the experiment. The results were expressed as relative infection percentages calculated by the following formula, 100 × (number of infected cells+25HOCh / number of infected cells -25HOCh). The means and standard deviations of a representative experiment were represented (n = 3). *, statistically < than cells transfected with ssGFP at p < 0.05 (Student's t-test).To further explore any possible correlations among CRP1-7 tridimensional structures and 25HOCh binding or antiviral effects, we next studied whether different oligomeric forms were present in ssCRP1-7.
Insect-made rCRPs suggest their different oligomerization states
The E.coli-made zebrafishc-reactive proteinCRP5 isoform (rCRP5) was crystallized as trimers (t-CRP5), as shown by X-ray studies [6]. However, it is not yet known whether trimers are the physiological form for the remaining CRP1-7 isoforms.Our first attempts to characterize CRP1-7 isoforms included expression in E.coli. However, numerous experiments met with irreproducibility, expression failure, high CRP denaturation or low yields, despite the reduction of autoinduction and temperature, and/or recloning of the best-producing clones (data not shown). Most probably some of those results could be explained by the toxicity of the rCRPs to E.coli.Alternatively, we explored the production of rCRP1/rCRP2/rCRP5/CRP7 in insect cells.The results showed that while insect-made rCRP2/rCRP5/rCRP7 could be expressed and purified by nondenaturing affinity chromatography, all attempts to purify rCRP1 were unsuccessful. Western blot analysis using anti-polyH antibodies indicated that although small amounts of rCRP1 were present, they were not retained by the affinity columns (data not shown), most likely due to polyH tail inaccessibility, perhaps because of a different conformation of rCRP1 compared with that of the other rCRPs.Polyacrylamide gel electrophoresis (PAGE) in the absence of SDS in the buffers, treating the samples under nondenaturing conditions (no heat, no SDS, no ß-mercaptoethanol and 1 mM CaCl2), and Western blotting with anti-p3 antibodies, showed that rCRP2 (calculated isoelectric point IP of 6.35) banded at an apparent molecular weight > 100 kDa, while rCRP5 (IP 4.6) and rCRP7 (IP 4.6) banded at ~ 75 kDa (Fig 6A left). A brief (2 min) treatment of the rCRP samples under denaturing conditions, increased the migration of all rCRP, especially that of rCRP7 (Fig 6A right). Although, in the absence of SDS, the estimation of the molecular weights is not accurate, the results suggested larger sizes for rCRP2/rCRP5 than for rCRP7, according to previous electrophoretic data described for p-hCRP and m-hCRP [63].
Fig 6
Polyacrylamide gel electrophoresis and Western blotting of rCRPs (A,B,C) and ssCRP1-7 (D). The insect-made affinity purified samples were electrophoresed in 4–20% gradient polyacrylamide gels. A) Samples of rCRPs prepared and electrophoresed in the absence of SDS in the buffers and stained with Coomassie (nondenaturing conditions). B) Samples of rCRPs heated at 100°C in the presence of ß-mercaptoethanol and SDS, electrophoresed in the presence of SDS in the buffers (denaturing conditions) and stained with Coomassie. C) Western blotting of the gel B transferred to nitrocellulose membranes, stained with anti-p3 antibody, peroxidase-labeled anti-rabbit and overexposed to diaminobenzidine (DAB) [37]. The ssCRP1-7 were electrophoresed in 15% polyacrylamide gels. D) Samples of ssCRP1-7 treated at 100°C in the presence of ß-mercaptoethanol and SDS, electrophoresed in the presence of SDS in the buffers, transferred to nitrocellulose membranes, stained with anti-actin (up) or anti-p3 (down) antibody, peroxidase-labeled anti-rabbit IgG and developed by chemiluminescence [7]. Similar results were obtained with samples electrophoresed under nondenaturing conditions (data not shown). Numbers around the gels, molecular weight markers in kDa. Up left arrow, position recognized by anti-actin antibodies. Down left arrow, position of purified rCRP5 recognized by anti-p3 antibodies. The results are representative of at least 3 experiments.
Polyacrylamide gel electrophoresis and Western blotting of rCRPs (A,B,C) and ssCRP1-7 (D). The insect-made affinity purified samples were electrophoresed in 4–20% gradient polyacrylamide gels. A) Samples of rCRPs prepared and electrophoresed in the absence of SDS in the buffers and stained with Coomassie (nondenaturing conditions). B) Samples of rCRPs heated at 100°C in the presence of ß-mercaptoethanol and SDS, electrophoresed in the presence of SDS in the buffers (denaturing conditions) and stained with Coomassie. C) Western blotting of the gel B transferred to nitrocellulose membranes, stained with anti-p3 antibody, peroxidase-labeled anti-rabbit and overexposed to diaminobenzidine (DAB) [37]. The ssCRP1-7 were electrophoresed in 15% polyacrylamide gels. D) Samples of ssCRP1-7 treated at 100°C in the presence of ß-mercaptoethanol and SDS, electrophoresed in the presence of SDS in the buffers, transferred to nitrocellulose membranes, stained with anti-actin (up) or anti-p3 (down) antibody, peroxidase-labeled anti-rabbit IgG and developed by chemiluminescence [7]. Similar results were obtained with samples electrophoresed under nondenaturing conditions (data not shown). Numbers around the gels, molecular weight markers in kDa. Up left arrow, position recognized by anti-actin antibodies. Down left arrow, position of purified rCRP5 recognized by anti-p3 antibodies. The results are representative of at least 3 experiments.By contrast, by applying PAGE in the presence of SDS in the buffers, samples under nondenaturing conditions and Western blotting, all the rCRP displayed similar bands that could be interpreted as residual amounts of trimers (~75 kDa), dimers (~50 kDa) and monomers (~25 kDa) (Fig 6B, left). The number of monomers increased when the samples were briefly treated (2 min) under denaturing conditions; especially for rCRP7, only monomers were detected (Fig 6B, middle). All rCRP became homogeneously monomeric (~25 kDa) when the samples were treated for longer (5 min) under denaturing conditions (Fig 6B, right). The slightly different positions of the monomeric forms could be due to differences in their glycosylation, although posttranscriptional deimidation has also been described in cod CRPs to cause electrophoretic heterogeneity [64].The most likely explanation for all the above commented data suggest that, while insect-made rCRP2/rCRP5 may exist as an equilibrium among trimers, dimers and monomers, rCRP7 has a stronger tendency to form monomers.
Only monomeric CRP1-7 could be detected from enriched supernatants
Western blotting of ssCRP1-7 using anti-p3 antibodies, only detected CRP2-7 monomers of ~ 25 kDa with slightly different positions for each ssCRP2-7, with similar profiles under denaturing (Fig 6C, down), 20-fold lower SDS concentration (not shown)[65] and nondenaturing (data not shown) sample and buffer conditions. Similar CRP2-7 levels were present in ssCRP2-7 as shown using actin as an internal control marker (Fig 6C, up). In these experiments, it was not possible to detect the presence of any CRP1 band, most likely because of its lower concentration, because previous results have demonstrated its presence by dot-blot analysis when using concentrated ssCRP1 [7]. Therefore, most likely, all ssCRP1-7 were secreted from EPC transfected cells mainly as monomers. Tridimensional structure predictions were used to further explore these possibilities.
In silico predictions of CRP1-7 tridimensional structures
To obtain more data on the possible tridimensional structures of CRP1-7, their amino acid sequences were modeled using the SWISS-MODEL web program. Automatic modeling showed that only CRP2/CRP5 rendered trimers, while the remaining of the CRP1-7 only modeled as monomers (Table 2). These results could be explained because CRP2/CRP5 have differences in most of their modeling parameters, specially in their torsion-angle potentials, compared with the other CRP1-7 (Table 2). Because the existence of EST from zebrafish in the UniGene Bank classified as CRP5 transcript variants [6] offered another opportunity to test the reliability of the trimer/monomer predictions mentioned above, we explored these sequences by automatic modeling. The corresponding modeling results predicted that 97.8% of the 47 CRP5 longest variant sequences modelled as trimers such as CRP2/CRP5. The comparison of the CRP5 variant amino acid sequences demonstrated 2-3-times more variations downstream of position 200 than in the rest of the molecule (Fig 7, red). On the other hand, most amino acid variations among the CRP1-7 isoforms were in the PC-binding pockets or hCRP-homologous Ch-binding domain (Fig 7, blue or green rectangles, respectively). Therefore, these results predicted the tendency of CRP2, CRP5 and CRP5-transcript variants to oligomerize as trimers and prompted further studies about the biological significance of both CRP isoforms and variants.
Table 2
Parameter values of in silico-predicted CRP1-7 oligomeric structures.
isoform
Acc.number
Automatic SWISS prediction
QMEAN
Cß
AA
SO
TO
CRP1
XM_693995.4
monomer
-0.55
-1.36
-1.03
-1.03
0.01
CRP2
BC097160
homotrimer
0.77
-1.64
-1.08
-0.92
1.19
CRP3
BC154042
monomer
0.01
-1.15
-1.15
-1.03
0.51
CRP4
BC115188
monomer
-1.81
-1.65
-1.95
-1.33
-1.07
CRP5
BC121777
homotrimer
1.42
-0.71
-0.89
-0.60
1.62
CRP5-
Dr.124528-
97.8%
1.12
-0.90
-0.99
-0.68
1.30
47 variants
Dr.162306
homotrimers
±0.31
±0.5
±0.2
±0.4
±0.5
CRP6
BC162745
monomer
-0.45
-1.20
-1.17
-1.34
0.15
CRP7
BC150371
monomer
-0.42
-1.04
-1.22
-1.28
0.15
The CRP1-7 amino acid sequences [2] were modeled as tridimensional structures using the SWISS-MODEL server with automatic template selection. Additionally, 47 full-length CRP5 amino acid sequences were modeled from 73 zebrafish crp5 EST variants (UniGene Dr.124528-Dr.162306) [6]. QMEAN, estimation of the total similarity to the template, comprising 4 individual Z-score parameters (Cß, all-atom, solvation and torsion). The individual Z-scores compare the predicted tridimensional structures with the template as follows: i) Cß atoms of three consecutive amino acids (Cß), ii) all-atoms (AA), iii) solvation burial status of the residues (SO) and iv) torsion angle potentials (TO). Low QMEAN score values indicate low similarity to the template. High QMEAN score values indicate high similarity to the template. Bold, highest and/or lowest score values. Gray, CRP2/CRP5. The mean ± standard deviation (n = 47) of the calculated score values of the CRP5-transcript variants were represented.
Fig 7
Alignment among EST-derived amino acid sequences of CRP5-transcript variants.
Transcript variants corresponding to the zebrafish crp5 gene were retrieved from 73 ESTs obtained from different zebrafish tissues (UniGene Dr.124528-Dr.162306) [6]. The corresponding ORFs > 100 amino acids translated by the Virtual Ribosome software (http://www.cbs.dtu.dk/services/VirtualRibosome/) were numbered without the signal peptide (1FKNL…in CRP5) and were aligned to CRP5 (BC121777). The number of different amino acids per position was represented. The raw data (S6 Table) were smoothed using the cubic B-spline method (Origin Pro 2017, Northampton, MA, USA). Blue circles, cysteines. Blue rectangle, PC-binding pocket of hCRP. Green rectangles, Ch-binding residues of hCRP [16]. Black line, number of amino acids per position of CRP1-7. Red profile, number of amino acids per position of CRP5 transcript variants.
Alignment among EST-derived amino acid sequences of CRP5-transcript variants.
Transcript variants corresponding to the zebrafishcrp5 gene were retrieved from 73 ESTs obtained from different zebrafish tissues (UniGene Dr.124528-Dr.162306) [6]. The corresponding ORFs > 100 amino acids translated by the Virtual Ribosome software (http://www.cbs.dtu.dk/services/VirtualRibosome/) were numbered without the signal peptide (1FKNL…in CRP5) and were aligned to CRP5 (BC121777). The number of different amino acids per position was represented. The raw data (S6 Table) were smoothed using the cubic B-spline method (Origin Pro 2017, Northampton, MA, USA). Blue circles, cysteines. Blue rectangle, PC-binding pocket of hCRP. Green rectangles, Ch-binding residues of hCRP [16]. Black line, number of amino acids per position of CRP1-7. Red profile, number of amino acids per position of CRP5 transcript variants.The CRP1-7 amino acid sequences [2] were modeled as tridimensional structures using the SWISS-MODEL server with automatic template selection. Additionally, 47 full-length CRP5 amino acid sequences were modeled from 73 zebrafishcrp5 EST variants (UniGene Dr.124528-Dr.162306) [6]. QMEAN, estimation of the total similarity to the template, comprising 4 individual Z-score parameters (Cß, all-atom, solvation and torsion). The individual Z-scores compare the predicted tridimensional structures with the template as follows: i) Cß atoms of three consecutive amino acids (Cß), ii) all-atoms (AA), iii) solvation burial status of the residues (SO) and iv) torsion angle potentials (TO). Low QMEAN score values indicate low similarity to the template. High QMEAN score values indicate high similarity to the template. Bold, highest and/or lowest score values. Gray, CRP2/CRP5. The mean ± standard deviation (n = 47) of the calculated score values of the CRP5-transcript variants were represented.
Discussion
The PAGE/Western data and in silico predictions, together with the results of 25HOCh binding and enhancement of anti-SVCV effects by ssCRP1-7, may implicate more m-CRP1-7 rather than t-CRP1-7 in those biological functions. However, CRP1-7 may also physiologically exist as an equilibrium of trimers, dimers and monomers, as shown in the cases of CRP2/CRP5 and, to a lower extent CRP7. On the other hand, because m-hCRP can also be produced during in vitro manipulations, for instance, by treatments in the absence of Ca++ with urea, low-pH or low-salt buffers [65,66], the m-CRP1-7 detected in this work may have been produced by other in vitro manipulations (e.g., purification by affinity chromatography in the absence of Ca++ or transfection of EPC cells). We may also speculate that t-CRP1-7 or at least CRP2/CRP5 could preferentially exist in fish until an unknown stimulus triggers their conversion to m-CRP1-7 and/or viceversa. Similarly, circulating hCRP is pentameric (p-hCRP) [13] and converts to the monomeric form (m-hCRP) after interaction with any exposed phosphocholine heads and/or Ch-enriched lipid rafts of cellular membranes in damaged tissues [16,17,59,63]. It is tempting to speculate that t-CRP2/CRP5 may be functionally analogous to the circulating p-hCRP and m-CRP1-7 could be analogous to the converted m-hCRP. Alternatively, all zebrafish m-CRP1-7 may be synthesized de novo as monomers. We may also think of the possibility of heterologous CRP1-7 oligomers. However, any of these possibilities remains speculative until specific reagents could be developed to differentiate each of those isoforms.Together, the above commented evidence shows that the oligomeric state of CRP1-7 isoforms fine tunes their lipid binding and, at least, some of their resulting heterogeneity of biological functionalities, as suggested previously [2,6,7]. Thus, previous transcriptomic studies on zebrafishcrp1-7 genes have demonstrated differential transcript expression throughout tissues [67], in survivors of VHSV infection [20] and in rag1−/− mutants defective in adaptive immunity [21]. Additionally, unexpected isoform-dependent in vitro and in vivo anti-viral activities were recently described for zebrafishCRP1-7 [7], while similar activities have never been reported for hCRP, or for any other CRP. In all those studies, crp2/CRP2 and crp5/CRP5 transcripts/proteins were the most modulated during either bacterial and viral infections, correlating with the higher trimeric propensity of CRP2/CRP5 and in sharp contrast to crp1/CRP1 and crp7/CRP7 which had remained mostly unmodulated. These findings together with the preference of CRP1-7 for hydroxycholesterol derivatives shown in this work, revealed fish primitive anti-viral functional CRP1-7 diversity that may also be relevant to the single-gene-encoded hCRP.The relevance of these explorations in the CRP1-7lipid interactions with viral infection diseases may have important implications for human diseases. For instance, the abundance of oxidized Chs in humanatherosclerotic plaques amplifies the impact that hCRP-Ch interactions may have for vascular diseases and neurodegenerative disorders during viral infections [58,68,69].
Docking predictions to selected lipid-heads and Ch.
The CRP1-7 were SWISS-modeled using the 3D structures CRP5 (GenBank accession number JF772178.1), 4PBP.pdb (+Ca) and 4PBO.pdb (-Ca) as templates. The structures of the lipid heads and cholesterol were extracted from *.sdf from PubChem (https://pubchem.ncbi.nlm.nih.gov/search/search.cgi) and converted to *.pdbqt using the Babel program from the PyRx package. Dockings were performed with a grid of 50x50x50 Angstrom. Yellow background, data used to derive Fig 1A.(XLSX)Click here for additional data file.
CRP1-7 docking predictions to several Ch-related physiological molecules in the absence and presence of Ca++.
CRP1-7 models, Ch-related physiological molecules and ΔG predictions were obtained as described in the legend of Fig 2. Numbers before the names_, PubMed ID numbers. HO, hydroxy. Ch, cholesterol.(XLSX)Click here for additional data file.
Docking predictions of binding of Ch-related nonphysiological compounds to CRP1-7.
Ch-related nonphysiological compound structures were retrieved from several libraries obtained from PubChem in a *.sdf format. To construct the library, 550 Chs, 314 colestens, 73 corticosterones, 41 dehydroepiandrosterones (DHEAs), 107 estriols, 99 pregnenolones, 196 progesterones and 107 HOChs were retrieved. Duplicated and extremely long molecules were eliminated from a total of 1487 *.sdf, resulting in a downsized library of 1093 *.pdbqt archives. The docking were performed to CRP1-7 modelled in the absence or in the presence of Ca++ (crp ±Ca++). A) Table of Ch-related compounds ordered from the lowest to the highest ΔG (free-binding energies) in Kcal/mol after docking to CRP1-7. Yellow background, data used to derive Table 1. B) Distribution of ΔG in relative frequencies. Black arrow, cut-off ΔG value chosen to derive Table 1. C) Correlation between the ΔGs from the dockings using CRP +Ca++ and CRP-Ca++.(XLSX)Click here for additional data file.
ssCRP1-7 binding to solid-phase 25HOCh.
The binding of ssCRP1-7 to 25HOCh was assayed using plates of 96-wells coated to dryness with 0.15 to 500 μM 25HOCh dissolved in ethanol. The 25HOCh-coated plates were washed with borate buffer and incubated with ssCRP1-7 in borate buffer for 1 h in a 50 μl volume. Bound ssCRP1-7 were detected using rabbit anti-CRP p3 peptide, peroxidase labeled goat anti-rabbit IgG and OPD. Raw absorbances were measured at 492–620 nm. Absorbance obtained with empty wells were subtracted to all data. Yellow background, data used to derive Fig 3B.(XLSX)Click here for additional data file.
Solid-phase binding and docking prediction raw data with their calculations of 25HOCh and the CRP5 pepscan interactions.
For the 25HOCh-binding, a series of 15-mer peptides overlapping 5 amino acids from the CRP5 sequence were chemically synthesized adding an amino-terminal biotin molecule. Solid-phases were coated with 2 μg per well of 25HOCh into polystyrene 96-well plates. Binding of 0.05 μg biotinylated pepscan peptides, detection with peroxidase-labelled streptavidin and staining with OPD were then performed. For the in silico docking predictions, the modeled pepscan peptides with the lowest ΔG energies in solution were docked to all possible conformations of 25HOCh. n° peptide, position of the middle amino acid of each 15-mer peptide of the pepscan. 1,2,3,4. . . ., number of replicas of 25HOCh-binding or predicted 25HOCh-CRP5 conformations of 25HOCh in the 25HOCh-CRP5 complexes. ±sd, standard deviations. Poses, list of ΔG of the predicted complexes for the different conformations of 25HOCh when docked to the CRP5peptides. docking best pose, the pose which resulted in the best fitting to the 25HOCh-binding data. Bold gray background, 25HOCh-binding data which was represented in Fig 4A which was represented in Fig 4A. Bold yellow background, predicted Kcal/mol ΔG of peptide docking to 25HOCh which best fitted the binding data. *, non-significant highest ΔG energies > -1.1 were adjusted to -2.5 Kcal/mol for best fitting the binding data.(XLSX)Click here for additional data file.
Number of amino acids per position after alignement among EST-derived amino acid sequences of CRP5 and CRP5 transcript variants.
Transcript variants corresponding to the zebrafishcrp5 gene were retrieved from UniGene Dr.124528-Dr.162306. ORFs > 100 amino acids were translated by the Virtual Ribosome software (http://www.cbs.dtu.dk/services/VirtualRibosome/), numbered without their signal peptides (1FKNL…in CRP5) and aligned to the sequence of CRP5 (BC121777). Amino acid, amino acids written in the three or single letter code. Number, different amino acids per position in CRP5 and CRP5 EST-derived variants.(XLSX)Click here for additional data file.
Authors: A M Estepa; A I Rocha; V Mas; L Pérez; J A Encinar; E Nuñez; A Fernandez; J M Gonzalez Ros; F Gavilanes; J M Coll Journal: J Biol Chem Date: 2001-10-04 Impact factor: 5.157
Authors: P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk Journal: Anal Biochem Date: 1985-10 Impact factor: 3.365
Authors: Punya Shrivastava-Ranjan; Éric Bergeron; Ayan K Chakrabarti; César G Albariño; Mike Flint; Stuart T Nichol; Christina F Spiropoulou Journal: MBio Date: 2016-12-20 Impact factor: 7.867
Authors: Alberto Falco; Mikolaj Adamek; Patricia Pereiro; David Hoole; José Antonio Encinar; Beatriz Novoa; Ricardo Mallavia Journal: Mar Drugs Date: 2022-05-28 Impact factor: 6.085
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391
Authors: Mikolaj Adamek; Jonathan Davies; Alexander Beck; Lisa Jordan; Anna M Becker; Miriam Mojzesz; Krzysztof Rakus; Typhaine Rumiac; Bertrand Collet; Graham Brogden; Keith Way; Sven M Bergmann; Jun Zou; Dieter Steinhagen Journal: Front Immunol Date: 2021-02-24 Impact factor: 7.561